Next Article in Journal
Recent Advances in the Use of Galleria mellonella Model to Study Immune Responses against Human Pathogens
Next Article in Special Issue
Special Issue: Treatments for Fungal Infections
Previous Article in Journal
A Ketoconazole Susceptibility Test for Malassezia pachydermatis Using Modified Leeming–Notman Agar
Previous Article in Special Issue
Therapy of Non-Dermatophytic Mycoses in Animals
Open AccessReview

Therapy and Management of Pneumocystis jirovecii Infection

Public Health Wales Microbiology Cardiff, UHW, Heath Park, Cardiff CF14 4XW, UK
*
Author to whom correspondence should be addressed.
J. Fungi 2018, 4(4), 127; https://doi.org/10.3390/jof4040127
Received: 10 October 2018 / Revised: 8 November 2018 / Accepted: 11 November 2018 / Published: 22 November 2018
(This article belongs to the Special Issue Treatments for Fungal Infections)
The rates of Pneumocystis pneumonia (PcP) are increasing in the HIV-negative susceptible population. Guidance for the prophylaxis and treatment of PcP in HIV, haematology, and solid-organ transplant (SOT) recipients is available, although for many other populations (e.g., auto-immune disorders) there remains an urgent need for recommendations. The main drug for both prophylaxis and treatment of PcP is trimethoprim/sulfamethoxazole, but resistance to this therapy is emerging, placing further emphasis on the need to make a mycological diagnosis using molecular based methods. Outbreaks in SOT recipients, particularly renal transplants, are increasingly described, and likely caused by human-to-human spread, highlighting the need for efficient infection control policies and sensitive diagnostic assays. Widespread prophylaxis is the best measure to gain control of outbreak situations. This review will summarize diagnostic options, cover prophylactic and therapeutic management in the main at risk populations, while also covering aspects of managing resistant disease, outbreak situations, and paediatric PcP. View Full-Text
Keywords: Pneumocystis pneumonia; PcP therapy; PcP diagnosis Pneumocystis pneumonia; PcP therapy; PcP diagnosis
Show Figures

Figure 1

MDPI and ACS Style

White, P.L.; Price, J.S.; Backx, M. Therapy and Management of Pneumocystis jirovecii Infection. J. Fungi 2018, 4, 127. https://doi.org/10.3390/jof4040127

AMA Style

White PL, Price JS, Backx M. Therapy and Management of Pneumocystis jirovecii Infection. Journal of Fungi. 2018; 4(4):127. https://doi.org/10.3390/jof4040127

Chicago/Turabian Style

White, P. L.; Price, Jessica S.; Backx, Matthijs. 2018. "Therapy and Management of Pneumocystis jirovecii Infection" J. Fungi 4, no. 4: 127. https://doi.org/10.3390/jof4040127

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop